31st week of 2009 patent applcation highlights part 42 |
Patent application number | Title | Published |
20090192122 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR -
A medicament having inhibitory activity against NF-κB activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient:
| 2009-07-30 |
20090192123 | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of Thrombin and/or by elevated expression of Thrombin receptors - A method of treatment of the human or non-human animal body for treating or preventing disorders caused by elevated thrombin or elevated thrombin receptor expression is disclosed, for example thromboembolic disease vascular syndromes, or proliferative diseases, which method comprises administering to a human or non-human animal body in need of such treatment an effective amount of a pharmaceutical composition containing dipyridamole, mopidamole or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions as well as the use of dipyridamole or mopidamole for the manufacture of these pharmaceutical compositions. | 2009-07-30 |
20090192124 | USE OF CERAMIDES FOR DEPIGMENTING THE SKIN - The invention relates to the use, as agent for depigmenting and/or whitening the skin, in particular for eliminating pigmentary spots and/or senescence spots, and/or as anti-browning agents, of a compound of formula (I): | 2009-07-30 |
20090192125 | Local anti-infective agent for treatment of nail fungal infections - A topical composition for treating nail fungal infections that utilizes an acidic antifungal agent with a molecular weight no greater than 170 Daltons in a formulation having a pH less than or equal to the pKa of the acidic antifungal agent plus one. Possible antifungal agents include omadine, octanoic acid, sorbic acid, hexanoic acid, and benzoic acid. The antifungal agent can be combined with a delivery system such as a lacquer, a gel, a patch, or a hydrating system. A second therapeutic agent such as a 5-fluorocystine or terbinafine can be included. | 2009-07-30 |
20090192126 | Oral Composition Comprising a Polyunsaturated Fatty Acid and Salicylic Acid for Obtaining an Antiinflammatory Effect in Skin - A composition which is adapted for oral consumption and which is in the form of a substantially homogeneous aqueous emulsion, suspension or dispersion comprising salicylic acid, or a C1 to C6 alkyl ester thereof, and docosahexaenoic acid (DHA) can exhibit an anti-inflammatory effect in skin. | 2009-07-30 |
20090192127 | Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment - The present invention relates to pharmaceutical compositions and combinations for treating cancer, comprising a diaryl urea compound e.g. 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and an PI3K/AKT signaling pathway inhibitor The PI3K/AKI signaling pathway inhibitor comprises PI3 inhibitors {like celecoxilo, viridins, wortmannins}, AKT kinase inhibitors {like perifosine, triciribine} and mTOR inhibitors {like the rapamycins temsirolimus and evorolimus}. | 2009-07-30 |
20090192128 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM - The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a Arg389Arg polymorphism and/or a Gly389Gly polymorphism in the beta 1 adrenergic receptor gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate. | 2009-07-30 |
20090192129 | BICYCLIC PYRROLE DERIVATIVES - Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) | 2009-07-30 |
20090192130 | Method for Treating Uterine Fibroids - The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids. | 2009-07-30 |
20090192131 | Pharmaceutical Composition - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 2009-07-30 |
20090192132 | Pharmaceutical Composition - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 2009-07-30 |
20090192133 | TREATMENT FOR ACHONDROPLASIA - The present application provides, inter alia, methods of treating disorders mediated by FGFRs and methods of screening for Hsp90 inhibitor compounds. | 2009-07-30 |
20090192134 | Compounds - A compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof: and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders. | 2009-07-30 |
20090192135 | Human Niemann Pick C1-Like 1 Gene (NPC1L1) Polymorphisms and Methods of Use Thereof - The present invention relates to the identification and use of single nucleotide polymorphisms and haplotypes in the Niemann Pick C1-Like 1 (NPC1L1) gene. In particular, methods are provided for correlating NPC1L1 polymorphisms and haplo-types with the responsiveness of a pharmaceutically active compound administered to a human subject. The invention further relates to a method for estimating the responsiveness of a pharmaceutically active compound administered to a human subject which method comprises determining at least one polymorphism in the NPC1L1 gene. The methods are based on determining polymorphisms in the NPC1L1 gene and correlating the responsiveness of a pharmaceutically active compound in the human by reference to one or more polymorphism in NPC1L1. The invention further relates to isolated nucleic acids comprising within their sequence the polymorphisms as defined herein, to nucleic acid primers and oligonucleotide probes capable of hybridizing to such nucleic acids and to a diagnostic kit comprising one or more of such primers and probes for detecting a polymorphism in the NPC1L1 gene. | 2009-07-30 |
20090192136 | BENZOYL-PIPERAZINE DERIVATIVES - A compound of formula | 2009-07-30 |
20090192137 | Dialysis method - There is provided the use of a low molecular weight thrombin inhibitor for the manufacture of a medicament for the treatment by dialysis, particularly haemodialysis, of a patient in need of such treatment, in which the thrombin inhibitor is provided in the dialysing solution, as well as dialysing solutions and concentrates including low molecular weight thrombin inhibitors, such as melagatran. | 2009-07-30 |
20090192138 | COMPOUNDS - The invention provides novel deazaxanthine and deazahypoxanthine compounds. The compounds may be useful in the therapy of diseases and conditions in which dipeptidylpeptidase-IV (DPP-IV) is implicated. | 2009-07-30 |
20090192139 | CGRP RECEPTOR ANTAGONISTS - The present invention is directed to compounds of Formula I: | 2009-07-30 |
20090192140 | IAP BIR DOMAIN BINDING COMPOUNDS - Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: | 2009-07-30 |
20090192141 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME - The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids. | 2009-07-30 |
20090192142 | USE OF CARBAMAZEPINE DERIVATIVES FOR THE TREATMENT OF AGITATION IN DEMENTIA PATIENTS - The present invention relates to the use of a compound of formula (I) wherein R | 2009-07-30 |
20090192143 | Substituted diazepan orexin receptor antagonists - The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 2009-07-30 |
20090192144 | Imidazo Compounds - The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof in which R, R | 2009-07-30 |
20090192145 | Spiro-Imidazo Compounds - Novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof, in which R, R | 2009-07-30 |
20090192146 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF - The present invention provides substituted di-, tri-, tetra- and penta-sulfide compounds and compositions, and methods of using the same for the treatment and/or prevention of a cell proliferative disorder. The present invention also provides methods for preparing trisulfide compounds and compositions. | 2009-07-30 |
20090192147 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES - The invention relates to [a]-fused indole compounds of the Formula II, | 2009-07-30 |
20090192148 | Organic Compounds - The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. | 2009-07-30 |
20090192149 | Imidazo Compounds - The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof, in which R, R | 2009-07-30 |
20090192150 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY - The invention relates to compounds of the formula I | 2009-07-30 |
20090192151 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS - Disclosed herein are compounds useful in treating glaucoma, inflammatory bowel disease, the stimulation of hair growth, and the stimulation of the conversion of vellus hair to terminal hair. The compounds themselves are herein. | 2009-07-30 |
20090192152 | Novel Antigiardial Agents and Methods of Use Thereof - The present invention provides a method of preventing or treating one or more of the following medical conditions, or treating symptoms of one or more of the following medical conditions: amebic infections, giardiasis, estrogen deficient states, osteoporosis, cardiovascular heart disease, high cholesterol levels, hyperlipidemia, cancer by administering to a subject having, or predisposed to, one or more of the conditions, a therapeutically effective amount of a compound of the present invention and a pharmaceutically acceptable carrier. | 2009-07-30 |
20090192153 | NOVEL ADENINE COMPOUND - An adenine compound or its pharmaceutically acceptable salt as a medicament as shown following formula (1): | 2009-07-30 |
20090192154 | SULTAM DERIVATIVES - A sultam derivative of Formula (1) described below having inhibitory action for aggrecanase activity is provided. The sultam derivative of Formula (1) and a salt thereof exhibit strong inhibitory action for aggrecanase activity in a living body of a mammalian animal including human, and is useful, for example, as an active ingredient of a pharmaceutical agent for preventing and/or treating various diseases caused by degradation of aggrecan. | 2009-07-30 |
20090192155 | Identification of Compounds Suitable for Treating Ad - The invention provides a method of screening for compounds which inhibit the hyperphosphorylation of tau, and hence are suitable for treating AD and related conditions. | 2009-07-30 |
20090192156 | PHTHALAZINONE DERIVATIVES - A compound of the formula (I): | 2009-07-30 |
20090192157 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN - The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D/1B receptors, by administering to a patient in need thereof a therapeutically effective amount of an indole compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. The methods of the invention may further comprise the administration of additional therapeutic agent. The invention also features new compounds of Formula (I), pharmaceutical compositions thereof, and methods of resolving enantiomeric mixtures. | 2009-07-30 |
20090192158 | Methods for Treating or Preventing Neoplasias - The present invention is directed to a method for treating or preventing a neoplasia in a human patient in need of such treatment comprising administering to the patient a compound that inhibits microsomal prostaglandin E synthase-1 in an amount that is effective for treating or preventing the neoplasia. | 2009-07-30 |
20090192159 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS - Disclosed herein is a compound represented by the formula: | 2009-07-30 |
20090192160 | COMPOUNDS - The invention relates to compounds of formula (I) | 2009-07-30 |
20090192161 | Amorphous and Crystalline Forms of Aprepitant and Processes for the Preparation Thereof - An amorphous form of aprepitant and a process for its preparation is provided. Also provided are mixtures of polymorph Forms I and II of aprepitant and a process for the preparation thereof. | 2009-07-30 |
20090192162 | Phenoxy Acetic Acids as PPAR Delta Activators - The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-δ and should be useful for treating conditions mediated by the same. | 2009-07-30 |
20090192163 | Novel Compounds - The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation. | 2009-07-30 |
20090192164 | Treating agent of inflammatory bowel disease - The invention discloses treating agents of inflammatory bowel disease, which contain p38MAPkinase inhibitor having properties of antedrug as the active ingredient. | 2009-07-30 |
20090192165 | ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO - Disclosed are antimicrobial compositions for treating poultry and meat to substantially eliminate bacteria and microorganism harmful to human. The compositions include various combinations of an aliphatic heteroaryl salt, an aliphatic benzylalkyl ammonium salt, a dialiphatic dialkyl ammonium salt, a tetraalkyl ammonium salt and/or trichloromelamine. | 2009-07-30 |
20090192166 | METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS - A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enhancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse. | 2009-07-30 |
20090192167 | Insecticidal and fungicidal composition - An insecticidal and fungicidal composition capable of controlling crop diseases and insect pests at the same time by combining an insecticidal active ingredient and a fungicidal active ingredient is provided. The insecticidal and fungicidal composition is characterized by comprising as active ingredients a compound represented by the general formula (1) or (2) and a compound represented by the general formula (3) or (4). | 2009-07-30 |
20090192168 | Compounds, Compositions and Methods - Certain substituted urea derivatives modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 2009-07-30 |
20090192169 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators - Compounds of Formula I: | 2009-07-30 |
20090192170 | Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors - The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof (I), wherein: R | 2009-07-30 |
20090192171 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases. | 2009-07-30 |
20090192172 | 2-Alkyl-Cycloalk(en)yl-Carboxamides - Novel 2-alkylcycloalk(en)ylcarboxamides of the formula (I) | 2009-07-30 |
20090192173 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS - Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis. In certain embodiments, the present invention comprises compositions comprising novel substituted ethylene diamine compounds further comprising antitubercular agents such as rifampicin, isoniazid, pyrazinamide and ethambutol. | 2009-07-30 |
20090192174 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action - The present invention relates to a compound of general formula I: | 2009-07-30 |
20090192175 | INSECTICIDAL COMPOUNDS - Novel heteroaromatic compounds of formula (I): wherein A | 2009-07-30 |
20090192176 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES - The invention relates to 1H-pyrazolo[3,4-d]pyrimidine, purine, 7H-purin-8(9H)-one, 3H-[1,2,3]triazolo[4,5-d]pyrimidine, and thieno[3,2-d]pyrimidine compounds, compositions comprising the compounds, and methods for making and using the compounds. | 2009-07-30 |
20090192177 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors - This invention pertains to compounds which specifically inhibit the adenosine A | 2009-07-30 |
20090192178 | mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS - In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J | 2009-07-30 |
20090192179 | CHROMAN DERIVATIVES - The invention relates to novel chroman derivatives, stereoisomers and pharmaceutically acceptable salts of Formula I | 2009-07-30 |
20090192180 | Alpha-7 Nicotinic Receptor Agonists and Statins In Combination - Combinations of α7-nAChR agonists and statins, pharmaceutical compositions containing the same and methods of using the same useful for treatment or prophylaxis of neurological degenerative diseases. | 2009-07-30 |
20090192181 | PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 - Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a human or animal subject such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. | 2009-07-30 |
20090192182 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF - A compound represented by general formula (I): | 2009-07-30 |
20090192183 | Oxymorphone Controlled Release Formulations - The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief. | 2009-07-30 |
20090192184 | Crystalline Polymorphs of Topotecan Hydrochloride and Methods for the Preparation Thereof - The invention relates to two novel crystalline form of Topotecan hydrochloride (Ia) | 2009-07-30 |
20090192186 | BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES - The invention relates to biaryl substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. | 2009-07-30 |
20090192187 | DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC DRUG - Pharmaceutical formulation in the form of inhalable dry powder comprising particles of a pharmaceutically acceptable salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo [2.2.2]octane as active ingredient, and particles of a carrier made of a physiologically acceptable pharmacologically-inert material are effective for the prevention and/or treatment of a respiratory disease such as asthma and COPD. | 2009-07-30 |
20090192188 | TETRAHYDROISOQUINOLINE DERIVATIVES - This invention relates to novel tetrahydroisoquinoline derivatives, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a dual OX-1/OX-2 orexin antagonist. | 2009-07-30 |
20090192189 | TREATMENT OF CANCERS EXPRESSING P95 ERBB2 - The truncated ErbB2 receptor (p95 | 2009-07-30 |
20090192190 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR - Compounds of formula I, | 2009-07-30 |
20090192191 | Substituted hydroxamic acid derivatives as tnf inhibitors - The present invention relates to novel compounds of formula (I) and their pharmaceutically useful compositions as MMP and TNF inhibitors. | 2009-07-30 |
20090192192 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA - The present invention relates to the use of compounds as broad spectrum inhibitors of bacterial biofilm formation. In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative and Gram-positive bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of bacterial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens. | 2009-07-30 |
20090192193 | DIAGNOSTIC AGENT AND METHOD FOR DETECTION OF CANCER AND A MEANS FOR TREATMENT OF SAME - A method is disclosed for detecting colorectal carcinoma having at least one HERG potassium ion channel, where at least one HERG potassium channel is detected in a tissue biopsy of the human color or rectum. In addition, a method is disclosed for treating colorectal carcinoma having at least one HERG potassium channel in a patient in need of said treatment, which comprises the step of administering to said patient, a therapeutically effective amount of 4-[1-{2-(6-methyl-2-pyridinyl)ethyl-4-piperidinyl}carbonyl]methane-sulfoanilide 2HCl sufficient to treat the colorectal carcinoma having at least one HERG potassium channel by selectively blockading the HERG potassium channel. | 2009-07-30 |
20090192194 | Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them - A compound of formula (I) | 2009-07-30 |
20090192195 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) | 2009-07-30 |
20090192196 | Fungicide hydroximoyl-tetrazole derivatives - The present invention relates to hydroximoyl-tetrazole derivatives of formula (I) wherein T represent a tetrazolyl substituent, A represents a carbo- or heterocycle, L | 2009-07-30 |
20090192197 | NOVEL OXAZOLIDINONE DERIVATIVES - The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as | 2009-07-30 |
20090192198 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME - The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids. | 2009-07-30 |
20090192199 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION - Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists. to enhance brain neurotrophism. | 2009-07-30 |
20090192200 | POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF - Provided are sorafenib hemi-tosylate, polymorphs thereof, polymorphs of sorafenib tosylate, preparation thereof and pharmaceutical compositions thereof. | 2009-07-30 |
20090192201 | Composition and method for treating and preventing musculoskeletal and connective tissue disorders - The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent). | 2009-07-30 |
20090192202 | ANDROGEN MODULATORS - The present invention is directed to a new class of 4-cyano-phenoxy-alkyl carboxyl derivatives and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth. | 2009-07-30 |
20090192203 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families. | 2009-07-30 |
20090192204 | N-(2-THIAZOLYL)-AMIDE DERIVATIVES AS GSK-3 INHIBITORS - The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I) for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus. | 2009-07-30 |
20090192205 | PROCESS FOR RELEASE OF BIOLOGICALLY ACTIVE SPECIES - A process for the release of a biologically active species comprising the steps of:
| 2009-07-30 |
20090192206 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS - The present invention relates to a compound of formula (I) | 2009-07-30 |
20090192207 | Topical Formulations Comprising 1-N-Arylpyrazole Derivatives and Amitraz - The present invention provides for, inter alia, novel topical formulations comprising at least one 1-N-arypyrazole derivative and amitraz and to methods for treating, controlling, or preventing parasite infestations on mammals or birds The inventive formulations include spot-on, pour-on or spray formulations and may include a further ectoparasiticide, such as an IGR compound, an avermectin or milbemycin derivative, or a pyrethroid insecticides, and anthelmintics, such as benzimidazoles and imidazothiazoles. The inventive formulation provides a larger duration of parasite control at a faster rate of control. The inventive formula remains effective up to three months from the first application. Moreover, the inventive formulations prevent tick attachment to the animal, thereby providing protection against tick borne diseases. The ectoparasites which may be controlled, treated or prevented by the present invention includes ticks, fleas, mites, mange, lice, mosquitoes, flies and cattle grubs. | 2009-07-30 |
20090192208 | Pyrazole compounds and use thereof in noxious arthropod pests controlling composition - The present invention provides a pyrazole compound of formula (a): a noxious arthropod pests controlling composition containing the compound shown by the formula (a) as an active ingredient; and a method for controlling noxious arthropod pests comprising applying an effective amount of the compound shown by the formula (a). | 2009-07-30 |
20090192209 | Extended treatment of tumors through vessel occlusion with light activated drugs - Methods of treating diseases of a subject through selective occlusion of blood vessels. The methods include identifying and/or mapping the blood vessels supplying nutrients to the diseased or unwanted tissue, delivering an appropriate dose of an occlusion-forming photosensitizer to the subject, and exciting the photosensitizer with sufficient light irradiation in the vicinity of the blood vessels to cause vessel occlusion. The vessel occlusion cuts off nutrient supply to the diseased or unwanted tissue resulting in cell death of that tissue and any other tissue served by the occluded vessels. | 2009-07-30 |
20090192210 | POLYMORPHS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E- -2-PROPENAMIDE - Polymorphic forms of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide free base and salts thereof are prepared by various processes. | 2009-07-30 |
20090192211 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION - The invention relates to a combination which comprises (a) a cyclooxygenase-2 inhibitor (“COX-2 inhibitor”) and (b) a histone deacetylase inhibitor (“HDAI”) for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of pre-malignant colon lesions or a colon cancer or other malignancies in a mammal, particularly a human. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating pre-malignant colon lesions (e.g. polyps) and colon cancer, as well as other malignancies, in a mammal, particularly a human, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination. | 2009-07-30 |
20090192212 | Dithiol Compounds, Derivatives, and Uses Therefor - Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract. | 2009-07-30 |
20090192213 | Benzo[b]furane And Benzo[b]thiophene Derivatives - The present invention relates to benzo[b]furane and benzo[b]thiophene derivatives of the general formula IV as the free base or salts thereof and their use. | 2009-07-30 |
20090192214 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION - Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions. | 2009-07-30 |
20090192215 | Cytotoxin Compounds and Methods of Isolation - The present invention concerns groups of compounds derived from tunicates of the | 2009-07-30 |
20090192216 | Methods for the formulation and manufacture of artesunic acid for injection - A method for the manufacture of a sterile intravenous or intramuscular formulation of artesunic acid and the formulation are the subject of this invention. First the artesunic acid powder is sterilized with ethylene oxide and placed into a sterile container. The contained sterilized powder is then dissolved in sterile sodium phosphate buffered solution to produce an injectable intravenous or intramuscular formulation. The sodium phosphate dissolves and dilutes the artesunic acid powder without caking or frothing resulting in an improved drug product. The invention also relates to the formulation and a method of treating a patient with either uncomplicated or severe and complicated malaria. | 2009-07-30 |
20090192217 | METHOD AND COMPOSITION FOR TREATING ACNE USING LIGNAN COMPOUNDS - The present invention relates to a method and composition for treating acne using lignan compounds represented by Formula 1. More particularly, the invention relates to an antibacterial composition against acne-causing bacteria, containing lignan compounds represented by Formula 1, as well as a method for treating acne using the same. The lignan compounds represented by Formula 1 are excellent not only in the antibacterial activity of, inhibiting the growth of acne-causing bacteria, but also in thermal stability. Accordingly, the lignan compounds may be useful as antibacterial agents against the acne-causing bacteria, and acne treatment agents. | 2009-07-30 |
20090192218 | USE OF PHTHALIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES MELLITUS - The present invention relates to the use of a compound as effective agent for the prevention or treatment of diabetes mellitus in a mammal. Said compounds being selected from the group of phthalide derivatives and exhibit excellent blood glucose lowering effects and thus are effective agents in the prevention or treatment of diabetes mellitus in mammals. | 2009-07-30 |
20090192219 | STABILIZATION OF IODINE-CONTAINING BIOCIDES BY MEANS OF SPECIAL AZOLE COMPOUNDS - Specific azole compounds are outstandingly suitable for stabilizing iodine-containing biocides in industrial materials, more particularly in paints based on alkyd resin. | 2009-07-30 |
20090192220 | TREATMENT FOR SOLID TUMORS - A method for treating a solid tumor in a subject comprises administering to the subject an ACAT inhibitory compound or a prodrug thereof, for example avasimibe, wherein (a) the solid tumor is at least about 2 mm in diameter and (b) the compound or prodrug thereof is administered in an amount that is therapeutically effective, but ineffective to cause unacceptable toxicity to normoxic tissues. | 2009-07-30 |
20090192221 | CARBAMATE ANTIBIOTICS - The invention relates to the field of antibiotic compositions, both inside and outside the medical field. Presented is a new class of antibiotic compounds around the lead compound (3,4-dichloro-phenyl)-carbamic acid 2-isobutoxycarbonylamino-1-methyl-ethyl ester, which are especially useful for combating infections with gram-positive bacteria and especially MRSA. | 2009-07-30 |
20090192222 | MESOPHASIC FORMS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUGS AND METHODS OF USE - Mesophasic forms of (3S)-aminomethyl-5-hexanoic acid prodrugs and methods of preparing and methods of using mesophasic forms of (3S)-aminomethyl-5-hexanoic acid prodrugs are provided. | 2009-07-30 |